TXA Central is a resource for health professionals caring for patients with acute severe bleeding
When given within three hours of birth, tranexamic acid (TXA) reduces deaths due to bleeding in women with postpartum haemorrhage (PPH). However, for many women, the treatment of PPH is too late to prevent death. Over one-third of pregnant women in the world are anaemic and many are severely anaemic.
These women have an increased risk of PPH and suffer more severe outcomes if PPH occurs. There is an urgent need to identify a safe and effective way to reduce postpartum bleeding in anaemic women.
The WOMAN-2 trial investigates if we can use TXA to prevent PPH from happening in the first place
TXA for PPH – The WOMAN-2 Trial
The WOMAN-2 trial is an international, randomised, double-blind, and placebo-controlled trial that investigates giving tranexamic acid to prevent PPH and other severe outcomes in women with moderate and severe anaemia.
Click on watch, read or teach to access videos, publications, and training materials
TXAcentral is a resource for health professionals caring for people with acute bleeding
TXAcentral brings together randomised trial evidence on the effectiveness and safety of tranexamic acid
Data on many of the trials are also available at the freeBIRD website
Postpartum Haemorrhage (PPH) is the leading cause of maternal death worldwide, responsible for around 100 000 deaths each year. TXA given as quickly as possible after birth and no later than 3 hours, reduces death due to bleeding and the need for surgery to stop bleeding
Every year there are over 300 million surgical procedures worldwide. Bleeding is an important complication and many patients require a blood transfusion. TXA reduces blood loss in surgical patients by about one‐third. However, the effects of TXA on thromboembolic events and mortality in surgery are uncertain